How Sleep Disorders Silently Double Your Stroke Risk — and What to Do About It

Sleep disorders and stroke share a deeply intertwined, bidirectional relationship with major public health implications. This narrative review, published in Medical Sciences in August 2025, synthesizes current evidence across multiple sleep disorder categories — including OSA, insomnia, restless legs syndrome (RLS), circadian rhythm disturbances, and sleep-related movement disorders — and their roles both as stroke risk factors and as post-stroke sequelae.

OSA emerges as the most clinically significant sleep disorder in the stroke context. Meta-analyses confirm a pooled OSA prevalence of approximately 71% among stroke patients (defined by AHI >5 events/hour), with prevalence slightly higher in hemorrhagic versus ischemic stroke (82.7% vs. 67.5%). OSA confers roughly a twofold increased risk of incident stroke (RR ≈ 2.0), and a 50% increase in recurrent stroke or TIA. The pathological mechanisms are multifactorial: recurrent nocturnal hypoxia activates the sympathetic nervous system, elevating catecholamines, angiotensin II, and endothelin-1; promotes systemic inflammation and endothelial dysfunction; induces non-dipping and reverse-dipping nocturnal blood pressure patterns; and fosters arrhythmias, atherosclerosis, and paradoxical embolism. Stroke patients with pre-existing OSA face prolonged hospitalizations (average 14 additional days) and significantly worse functional outcomes.

Sleep duration follows a U-shaped risk curve: both short sleep (<7 hours) and long sleep (≥9 hours) independently elevate stroke risk. Sleeping fewer than 6 hours nearly doubles stroke odds (OR: 1.97), while long sleep is associated with higher rates of ischemic stroke and intracerebral hemorrhage. Optimal stroke prevention appears to require 7–9 hours nightly. These associations are particularly pronounced in women, middle-aged adults, and individuals with metabolic syndrome. Insomnia, affecting nearly 50% of stroke patients in the early post-stroke period, is independently linked to elevated anxiety, functional disability, depression, and cognitive impairment. Nocturnal hypertension — defined as sleep-time SBP ≥120 mmHg — carries a 2.65-fold elevated stroke risk and is an underappreciated therapeutic target.

The review also highlights substantial disparities in sleep disorder burden across racial, ethnic, and socioeconomic groups, with African Americans and Native Hawaiians/Pacific Islanders disproportionately reporting short sleep durations. Genetic studies have identified 84 loci associated with short sleep duration across diverse ancestries, suggesting heritable components that may interact with environmental exposures.

Therapeutically, CPAP remains the cornerstone of OSA management, with evidence linking its use to reductions in post-stroke depression, improvements in activities of daily living, and better cognitive performance. For CPAP-intolerant individuals, alternative approaches including oral appliances, positional therapy, and emerging neurostimulation options are discussed. The authors underscore critical gaps: non-OSA sleep disorders remain poorly studied in stroke populations, screening is inconsistent, and integration of sleep medicine into stroke care pathways is insufficient. They call for improved diagnostic tools, standardized screening protocols, and multidisciplinary care models.